Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.75 |
| ▸ | PGR | P06401 | 4/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TNF | P01375 | 2/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535419 | 1.00 | HIF1A (0.75) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL23760030 | 0.96 | HIF1A (0.73) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL23207755 | 0.93 | HIF1A (0.75) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL14501128 | 0.92 | HIF1A (0.74) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL12087295 | 0.92 | HIF1A (0.84) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL5148577 | 0.91 | HIF1A (0.72) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL11334051 | 0.91 | HIF1A (0.72) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL11339300 | 0.91 | HIF1A (0.72) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL5147408 | 0.91 | HIF1A (0.72) | HIF1ALMNANR3C1PGRCYP3A4 | |
| SCHEMBL11330830 | 0.91 | HIF1A (0.72) | HIF1ALMNANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858951-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-20230390270-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2023-12-07 | — | — | US | disclosed |
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-11691950-B2 | Isoquinoline-steroid conjugates and uses thereof | AERIE PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691950-B2 | Isoquinoline-steroid conjugates and uses thereof | AERIE PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| EP-4199927-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-111183142-B | Boric acid derivatives | 默克专利股份公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116096421-A | Methods for treating remission-type multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3672977-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| US-20220153761-A1 | Boronic Acid Derivatives | MERCK PATENT GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-11274109-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| WO-2022040369-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | BIOGEN MA INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20210300874-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | ALCON INC. (CH) | 2021-09-30 | — | — | US | disclosed |
| US-11059789-B2 | Isoquinoline-steroid conjugates and uses thereof | AERIE PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200071275-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | ALCON INC. (CH) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047496-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | AERIE PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153761-A1 | Boronic Acid Derivatives | PSMB7, PSMA7, BRD7 | HIF1A 879/4885LMNA 2820/4885NR3C1 2843/4885 |
| US-20200071275-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | GRK1, TNK2, CYP11B2 | HIF1A 3238/4885LMNA 1670/4885NR3C1 173/4885 |
| US-11059789-B2 | Isoquinoline-steroid conjugates and uses thereof | GRK1, TNK2, CYP11B2 | HIF1A 3238/4885LMNA 1670/4885NR3C1 173/4885 |
| US-11274109-B2 | Boronic acid derivatives | PSMB7, PSMA7, BRD7 | HIF1A 906/4885LMNA 2826/4885NR3C1 2848/4885 |
| US-20230390270-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | SGMS1, SGMS2, HMGCR | HIF1A 4216/4885LMNA 3952/4885NR3C1 490/4885 |
| US-11691950-B2 | Isoquinoline-steroid conjugates and uses thereof | GRK1, TNK2, CYP11B2 | HIF1A 3238/4885LMNA 1670/4885NR3C1 173/4885 |
| US-11858951-B2 | Boronic acid derivatives | PSMB7, PSMA7, BRD7 | HIF1A 879/4885LMNA 2820/4885NR3C1 2843/4885 |
| US-20210300874-A1 | ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF | GRK1, TNK2, CYP11B2 | HIF1A 3238/4885LMNA 1670/4885NR3C1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.